the novel protein homeostatic modulator btx306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

Small molecules targeting the cereblon-containing e3 ubiquitin ligase including thalidomide, lenalidomide, and pomalidomide modulate turnover of downstream client proteins and demonstrate pre-clinical and clinical anti-myeloma activity. different drugs that engage with cereblon hold the potential of unique phenotypic effects, and we therefore studied the novel protein homeostatic modulator (phm™) btx306 with a unique thiophene-fused scaffold bearing a substituted phenylurea and glutarimide. this agent much more potently reduced human-derived myeloma cell line viability, with median inhibitory concentrations in the single nanomolar range versus micromolar values for lenalidomide or pomalidomide, and more potently activated caspases 3/8/9. while lenalidomide and pomalidomide induced greater degradation of ikaros and aiolos in myeloma cells, btx306 more potently reduced levels of gspt1, erf1, ck1α, mcl-1, and c-myc. suppression of cereblon or overexpression of aiolos or ikaros induced relative resistance to btx306, and this agent did not impact viability of murine hematopoietic cells in an in vivo model, demonstrating its specificity for human cereblon. interestingly, btx306 did show some reduced activity in lenalidomide-resistant cell line models but nonetheless retained its nanomolar potency in vitro, overcame bortezomib resistance, and was equipotent against otherwise isogenic cell line models with either wild-type or knockout tp53. finally, btx306 demonstrated strong activity against primary cd138-positive plasma cells, showed enhanced anti-proliferative activity in combination with bortezomib and dexamethasone, and was effective in an in vivo systemic model of multiple myeloma. taken together, the data support further translational studies of btx306 and its derivatives to the clinic for patients with relapsed and/or refractory myeloma.